Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte(TM) Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Soligenix Invited to Present at Upcoming Investor Conferences
HyBryte(TM) Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Soligenix Announces Partnership with Sterling Pharma Solutions
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.